(Total Views: 987)
Posted On: 04/08/2020 5:08:55 PM
Post# of 148870
Here is what I confirmed with NP (and he has confirmed publicly):
NYSE: 1) $5 million shareholder’s equity, 2) 18 months cash, 3) $2.00 stock price
NASDAQ: 1) $5 million shareholder’s equity, 2) 12 months cash, 3) $4.00 stock price
They are pursuing NASDAQ.
See more info below:
https://marketnewsfirst.com/2020/03/09/cytody...-patients/
Nader Pourhassan: Absolutely yes. Thank you for your question. So please think about two different categories either Nasdaq or the New York Stock Exchange. We are in talks with the New York Stock Exchange of business the director of uplisting, Paul Dorfman and what he has told us is they need 18 month’s worth of cash that means our projected use of spending for 18 months they won’t give us credit for the revenue that we’re going to bring in because those are potential revenues. So if I was going to uplist to New York, if the company, I’m sorry if the company was going to obvious need the 18-months cash it has to be raised right now as in the past. We try to update they wanted that kind of thing and it would have delayed the company for 500 million shares we said no we will hang in there till we have better days and these are better days and December 16 and past so we’re not going to pursue New York Stock Exchange until we have perhaps a $100 million dollars debt deals done. In Nasdaq the amount of cash projection is for 12 months. You have to keep in mind that we signed a $60 million dollar agreement with Samsung this is the first payment but it is due in the next year or so and we are right now talking to selling that product for multiples of what it’s worth to other countries pre-made and even though it’s not made yet. The potential that we have here is just tremendous in my opinion and I just don’t suggest to anybody at this time for us to go and raise money even though people want us to raise money to meet that threshold of 18 months which could be $100 million dollars in the in case of 12 months $90 million dollars we will keep making publicity we will inject the first coronavirus patient, we will wait for our breakthrough designation, if the FDA says they need more patients we will give them more patients. We will go forward like we are standing a solid-gold because I think this company has really reached some major points. Craig, do you want to add anything to the obvious thing?
Craig Eastwood: No thanks Nader. I would say that yes of course an uplist remains a high priority of the company. We previously addressed this in other calls, but of course it brings broader access to capital and expanded shareholder base visibility and institutional interest, but in order I think very adequately characterized our current standing on that thank you so much thank you Nader.
NYSE: 1) $5 million shareholder’s equity, 2) 18 months cash, 3) $2.00 stock price
NASDAQ: 1) $5 million shareholder’s equity, 2) 12 months cash, 3) $4.00 stock price
They are pursuing NASDAQ.
See more info below:
https://marketnewsfirst.com/2020/03/09/cytody...-patients/
Nader Pourhassan: Absolutely yes. Thank you for your question. So please think about two different categories either Nasdaq or the New York Stock Exchange. We are in talks with the New York Stock Exchange of business the director of uplisting, Paul Dorfman and what he has told us is they need 18 month’s worth of cash that means our projected use of spending for 18 months they won’t give us credit for the revenue that we’re going to bring in because those are potential revenues. So if I was going to uplist to New York, if the company, I’m sorry if the company was going to obvious need the 18-months cash it has to be raised right now as in the past. We try to update they wanted that kind of thing and it would have delayed the company for 500 million shares we said no we will hang in there till we have better days and these are better days and December 16 and past so we’re not going to pursue New York Stock Exchange until we have perhaps a $100 million dollars debt deals done. In Nasdaq the amount of cash projection is for 12 months. You have to keep in mind that we signed a $60 million dollar agreement with Samsung this is the first payment but it is due in the next year or so and we are right now talking to selling that product for multiples of what it’s worth to other countries pre-made and even though it’s not made yet. The potential that we have here is just tremendous in my opinion and I just don’t suggest to anybody at this time for us to go and raise money even though people want us to raise money to meet that threshold of 18 months which could be $100 million dollars in the in case of 12 months $90 million dollars we will keep making publicity we will inject the first coronavirus patient, we will wait for our breakthrough designation, if the FDA says they need more patients we will give them more patients. We will go forward like we are standing a solid-gold because I think this company has really reached some major points. Craig, do you want to add anything to the obvious thing?
Craig Eastwood: No thanks Nader. I would say that yes of course an uplist remains a high priority of the company. We previously addressed this in other calls, but of course it brings broader access to capital and expanded shareholder base visibility and institutional interest, but in order I think very adequately characterized our current standing on that thank you so much thank you Nader.
(4)
(0)Scroll down for more posts ▼
